[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Bakulev Scientific Center of Cardiovascular Surgery\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":154},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,52,98,131],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":32,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100535528","radiofrequency-and-cryoablation-of-the-posterior-wall-of-the-left-atrium-100535528",false,"NCT06253000","Radiofrequency and Cryoablation of the Posterior Wall of the Left Atrium","Comparative Analysis of Radiofrequency and Cryoablation of the Posterior Wall of the Left Atrium in Patients With Persistent Atrial Fibrillation","Inclusion Criteria:\n\n* Age over 18 years old;\n* Atrial fibrillation resistant to antiarrhythmic therapy;\n* Persistent and long-persisting form of atrial fibrillation;\n* The patient's consent to participate in the study.\n\nExclusion Criteria:\n\n* Age under 18 and over 80 years old;\n* The presence of another cardiac pathology requiring surgical treatment;\n* Congenital heart defects;\n* Previous \"open\" cardiac surgery;\n* Bone marrow diseases;\n* Pathology of the blood coagulation system;\n* The left ventricular ejection fraction is less than 40%;\n* Moderate to severe renal insufficiency (creatinine clearance \\\u003C50 ml\u002Fmin);\n* Drug-resistant hypertension (despite hypotensive therapy);\n* Organically altered mitral valve;\n* There are reasons to assume that the patient will not show up for subsequent visits (control points of the study) for various reasons;\n* The patient's participation in another clinical trial.","ALL","18 Years","80 Years",{"count":20,"type":21},158,"ESTIMATED","INTERVENTIONAL",[24],"NA","Atrial fibrillation (AF) is the cause of 20% of strokes, and the risk of stroke in a person suffering from this arrhythmia increases by 5 times. Ischemic stroke in patients with AF is often fatal and, compared with stroke of other etiology, leads to the most pronounced disability and more often recurs. Accordingly, the risk of death in patients with AF-related stroke is 2 times higher, and treatment costs increase 1.5 times.\n\nThe main interventional method of treating AF, available in most medical institutions, is the use of radio frequency and\u002For cryoenergy to eliminate destructive damage to the left atrium (LA).\n\nThe aim of this study is to compare two different interventional methods and identify predictors of recurrence in patients with persistent and long-term AF.",[27,28,29,30,31],"Stroke","Acute Cerebrovascular Accident","Transient Ischemic Attack","Death","Atrial Fibrillation Recurrent",[33,34,35,36,37,38],"atrial fibrillation","radiofrequency ablation","cryoablation","left atrium","the posterior wall of the left atrium","atrial remodeling","RECRUITING","2026-05-07",{"date":42,"type":43},"2026-05-08","ACTUAL",{"date":45,"type":43},"2023-06-10",{"date":47,"type":21},"2026-12-30",{"name":49,"class":50},"Bakulev Scientific Center of Cardiovascular Surgery","OTHER_GOV",1,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":60,"sex":16,"minAge":61,"maxAge":62,"enrollmentInfo":63,"targetDuration":4,"studyType":22,"phases":65,"briefSummary":66,"conditions":67,"keywords":72,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":51},"100537743","neuromodulation-of-the-autonomic-nervous-system-in-athletes-100537743","NCT06281795","Neuromodulation of the Autonomic Nervous System in Athletes","Neuromodulation of the Autonomic Nervous System in Athletes (NANSA Trial)","NANSA","Inclusion Criteria:\n\n* Professional athletes over the age of 15 and under the age of 35;\n* Cyclic sports (swimming, modern pentathlon, athletics, triathlon);\n* Difficult coordination sports (dance sports, rhythmic gymnastics);\n* Sports category: no lower than candidate for master of sports;\n* Voluntary informed consent.\n\nExclusion Criteria:\n\n* Atypical and unrelated to physical exertion changes on the ECG (T wave inversion, st-segment depression, pathological Q waves, signs of left atrial enlargement, signs of right ventricular hypertrophy, ventricular pre-excitation, complete right or left bundle branch block, prolonged or shortened Q-T interval, Brugada-like early repolarization);\n* Heart rhythm and conduction disorders (frequent ventricular and supraventricular extrasystoles, first-degree atrioventricular block (P-Q \\> 0.21 s, not shortened during hyperventilation or physical exertion), second or third degree);\n* Expressed sinus bradycardia with resting heart rate \\\u003C 40 bpm;\n* Taking glucocorticosteroids in the last 1 month;\n* Taking any antiarrhythmic drugs, including beta-blockers.",true,"15 Years","35 Years",{"count":64,"type":21},125,[24],"There are few studies in the literature that have evaluated the effects of using percutaneous stimulation of the auricular branch of the vagus nerve for sports purposes (to accelerate recovery after physical exertion). It has been demonstrated that tVNS in athletes improved the rate of heart rate recovery, reduced lactic acid levels in blood plasma, reduced pain, reduced overtraining syndrome and fatigue levels.",[68,69,70,71],"Efficacy, Self","Fatigue; Muscle, Heart","Fatigue, Mental","Fatigue; Combat",[73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89],"auricular stimulation","auricular vagus nerve stimulation","transcutaneous vagus nerve stimulation (tVNS)","vagus nerve stimulation (VNS)","heart rate","heart rate variability","power of high-frequency oscillations (HF)","power of low-frequency oscillations (LF)","LF\u002FHF","index centralization (IC)","index of vegetative balance (IVB)","athletes","sport","maximum oxygen consumption (VO2max)","treadmill speed","anaerobic threshold of metabolism.","aerobic metabolism threshold of metabolism","2025-06-23",{"date":92,"type":43},"2025-06-26",{"date":94,"type":43},"2024-04-01",{"date":96,"type":21},"2026-01-31",{"name":49,"class":50},{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":4,"eligibilityCriteria":104,"healthyVolunteers":11,"sex":16,"minAge":105,"maxAge":106,"enrollmentInfo":107,"targetDuration":4,"studyType":22,"phases":109,"briefSummary":110,"conditions":111,"keywords":115,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":51},"100515496","auricular-vagus-stimulation-and-stemi-100515496","NCT05992259","Auricular Vagus Stimulation and STEMI","Auricular Vagus Stimulation and ST-Segment Elevation Myocardial Infarction","Inclusion Criteria:\n\n* patients with STEMI who have signed an informed voluntary consent to participate in the study;\n* primary myocardial infarction;\n* treatment in the first 12 hours from the onset of pain syndrome;\n* primary PCI.\n\nExclusion Criteria:\n\n* acute heart failure III-IV;\n* bradyarrhythmias;\n* atrial fibrillation\u002Fflutter at the time of switching on;\n* Thrombolytic therapy at the prehospital stage;\n* a history of myocardial infarction;\n* PCI\u002Fcoronary artery bypass grafting (CABG) in the anamnesis.","40 Years","75 Years",{"count":108,"type":21},300,[24],"At the moment, the invasive strategy for the infarct-associated coronary artery in patients with ST-segment elevation myocardial infarction (STEMI) necessary to save the myocardium and reduce the size of the necrosis zone remains the leading one. However, despite the high efficiency of providing medical care to patients with acute coronary syndrome (ACS), there remains a high mortality and disability of this group of patients. In this regard, the search for new drug and non-drug strategies for the treatment of patients with ACS is actively continuing. Over the past decade, it has been shown that transcutaneous vagus nerve stimulation (TENS) has a cardioprotective effect both in chronic heart failure and in coronary heart disease, improves cardiac function, prevents reperfusion injury, weakens myocardial remodeling, increases the effectiveness of defibrillation and reduces the size of a heart attack. One of the methods of noninvasive stimulation of the afferent fibers of the vagus nerve is percutaneous electrical stimulation of the auricular branch of the vagus nerve. However, further studies are needed to determine whether stimulation of the tragus can improve the long-term clinical outcome in this cohort of patients.",[112,113,114],"Vagus Nerve Stimulation","Acute Coronary Syndrome","Ischemia Reperfusion Injury",[73,74,116,76,117,118,119,120,121,122,33],"transcutaneous vagus nerve stimulation (TENS)","acute coronary syndrome","myocardial ischemia reperfusion injury","ST-segment elevation myocardial infarction","coronary heart disease","acute myocardial infarction","mortality","2025-06-17",{"date":125,"type":43},"2025-06-18",{"date":127,"type":43},"2022-09-01",{"date":129,"type":21},"2026-12-01",{"name":49,"class":50},{"id":132,"slug":133,"hasResults":11,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":4,"eligibilityCriteria":137,"healthyVolunteers":60,"sex":16,"minAge":17,"maxAge":106,"enrollmentInfo":138,"targetDuration":4,"studyType":22,"phases":140,"briefSummary":141,"conditions":142,"keywords":144,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":147,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":153},"100491531","auricular-vagus-stimulation-and-heart-rate-variability-100491531","NCT05680337","Auricular Vagus Stimulation and Heart Rate Variability","Transcutaneous Electrical Auricular Vagus Stimulation and Heart Rate Variability","Inclusion Criteria:\n\n* Sinus rhythm at the time of registration\n\nExclusion Criteria:\n\n* Frequent ventricular \u002F supraventricular extrasystole, 2d\u002F3d degree AV Block\n* Taking glucocorticosteroids in the last 1 month\n* Taking any antiarrhythmics, except beta blockers\n* Severe chronic renal or liver pathology",{"count":139,"type":21},600,[24],"Transcutaneous electrical stimulation of the auricular vagus nerve (TENS) is a promising method of neuromodulation of the autonomic nervous system in patients with various pathologies. The use of this method requires the determination of a reliable biomarker of successful activation of the vagus nerve using TENS. Currently, most studies focus on the assessment of heart rate variability (HRV) as a marker of the functioning of the autonomic nervous system.\n\nDespite the physiological justification of HRV as a biomarker for TENS, the data on the effects of TENS on HRV are ambiguous. In some studies, a significant decrease in the ratio of spectral characteristics (LF\u002FHF) in active TENS was found in comparison with fictitious stimulation (sham), which indicated an increase in the parasympathetic component of HRV. However, other studies have not revealed an increase in HRV.",[112,143],"Heart Rate Variability",[73,74,77,116,76,78,79,80,145,146,81,82,83],"power of very low frequency oscillations (VLF)","power of ultra-low frequency oscillations (ULF)",{"date":125,"type":43},{"date":149,"type":43},"2022-12-01",{"date":151,"type":21},"2026-07-01",{"name":49,"class":50},3,""]